Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure

Anti-Cancer Drugs

Volumn 10, Issue 6, 1999, Pages 617-623

  Schmitt, C ^e   Blijham, G ^a   Jolain, B ^b   Rougier, P ^c   Van Cutsem, E ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SANOFI   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e ARCOS   (France)

Author keywords

5 Fluorouracil; Colorectal cancer; Irinotecan; Medical care consumption; Phase III

Indexed keywords

FLUOROURACIL; IRINOTECAN;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG TOXICITY; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

EID: 0032846903     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199907000-00014     Document Type: Article

References (13)

1. 1. Van Cutsem E, Rougier P, Droz JP, Marty M, Bleiberg H. Clinical benefits of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU. Proc Am Soc Clin Oncol 1997; 16: 268a (abstr 950).
2. 2. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pre-treated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60.
3. 3. Rougier P, Van Cutsem E, Bajetta E, et al. Phase III trial of Irinotecan versus infusional fluorouracil in patients with metastatic colorectal cancer after fluorouracil failure. Lancet 1998; in press.
4. 4. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997; 53: 419-34.
5. 5. Zhao H, Tsiatis AA. A consistent estimator for the distribution of quality adjusted survival time. Biometrika 1997; 84: 339-48.
6. 6. Ross P, Heron J, Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer 1996; 32A (suppl 5) S13-7.
7. 7. Torfs K, Pocceschi S. A retrospective study of resource utilisation in the treatment of advanced colorectal cancer in Europe. Eur J Cancer 1996; 32A (suppl 5) S28-31.
8. 8. Jönsson B, Weinstein MC. Economic evaluation alongside multinational clinical trials, study considerations for GUSTO Ib. Int J Technol Assess Health Care 1997; 13: 49-58.
9. 9. Drummond ME, Bloom BS, Carrin G, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992; 8: 671-82.
10. 10. Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-74.
11. 11. de Gramont A, Bosset J-F, Milan C, et al. Randomised trial comparing low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J Clin Oncol 1997; 15: 808-15.
12. 12. Weh HJ, Wilke HJ, Dierlamm J, et al. Weekly therapy with folinic acid (FA) and high-dose fluorouracil (5-FU) 24 hour infusion in pre-treated patients with metastatic colorectal carcinoma. A multicentre study by the Association of Medical Oncology of the German Cancer Society. Ann Oncol 1994; 5: 233-7.
13. 13. Ardalan B, Chua L, Tiang E-M, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991; 9: 623-30.